The NIH-funded CADET program, administered by BioVentures, will provide cancer researchers with the entrepreneurial training and mentorship needed to bring lab discoveries to patients. Applications are open until October 31.
Newly granted patent: U.S. Patent No. 12,370,338 B2, “Immersive Distraction Therapy.
Join us on October 22, from 4–6 PM at the Jack Stephens Spine Institute (12th Floor) for the next UAMS Showcase of Medical Discoveries, focused on UAMS intellectual property and
We were excited to host the kickoff meeting for one of our newest startups, OncoRock Therapeutics, right here at BioVentures! OncoRock is a biotechnology startup dedicated to transforming academic discoveries
Do you have a passion for advancing scientific innovation through program leadership? BioVentures is looking for a Research Program Manager to help us build the future of biomedical entrepreneurship and
We’re proud to share that our Senior Licensing Associate, Megan Reed PhD, MBA has been selected as a 2025 recipient of the Susan Riley Keyes Memorial Fellowship from the AUTM
Newly granted patent: U.S. Patent No. 12,268,674 B2, “Mi-2β Inhibitor as an Immunotherapy Agent” What’s the problem? Immune checkpoint therapies, such as anti-PD-1 antibodies (e.g. Keytruda, Opdivo), have transformed cancer
BioVentures will be present at the Translational Research Institute (TRI) Research Expo 2025, taking place Wednesday, September 10, from 4:00 to 6:00 p.m. CDT at the Reynolds Institute on Aging,
Stefanie Kennon-McGill, Ph.D., Senior Program Manager at BioVentures LLC, will be the featured speaker at 2 p.m. Wednesday, August 27, for the Health Sciences Entrepreneurship Grand Rounds. The topic will be “Leveraging
Curious how an idea becomes a protected invention at UAMS? At BioVentures, we guide innovators through every step, from disclosure to patent decisions and market strategy. Here’s how the process
BioVentures supported University of Arkansas for Medical Sciences (UAMS) first-year medical students this summer through the Partnership in Cancer Research (PCAR) program. Over eight weeks, participants worked in multidisciplinary teams
Newly granted patent: U.S. Patent No. 12,281,171 B2, “Periostin Antibodies and Methods of Using the Same” What’s the problem? Some cancers create a unique “signal” by adding a rare sugar modification
DISCLAIMER: Information on this website is not legal advice and should not be relied on as such. The law can change and the information contained on this site may be outdated, so you should always consult an attorney regarding your specific issues in view of the current state of the law. Please contact our team at bioventures@uams.edu if you have any questions and we can help determine a course of action.
